1.81

0.00% +0.00

After Hours: 1.75 -0.06 -3.31%

I-Mab ADR (IMAB)

Overview News Price History Option Chain Discussions Forecast

I-Mab ADR stock is currently priced at $1.81, with a 24-hour trading volume of 283.72K. It has seen a +0.00% increased in the last 24 hours and a -2.69% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.81 pivot point. If it approaches the $1.82 resistance level, significant changes may occur.

Previous Close:

$1.81

Open:

$1.8

24h Volume:

283.72K

Market Cap:

$146.07M

Revenue:

$-35.63M

Net Income/Loss:

$-315.57M

P/E Ratio:

-0.4756

EPS:

-3.8057

Net Cash Flow:

$-167.78M

1W Performance:

+0.56%

1M Performance:

-2.69%

6M Performance:

+49.59%

1Y Performance:

-42.36%

1D Range:

$1.78

$1.81

52W Range:

$1.16

$3.45

I-Mab ADR Stock (IMAB) Company Profile

Name

I-Mab ADR

Sector

Healthcare (1197)

Industry

Biotechnology (688)

Phone

86 21 6057 8000

Address

West Tower, OmniVision, Suite 802 88 Shangke Road Pudong District, Shanghai

Employee

185

Twitter

Next Earnings Date

2024-03-28

Latest SEC Filings

IMAB's Discussions on Twitter

I-Mab ADR Stock (IMAB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-09-21	Initiated	Siebert Williams Shank	Buy
Jun-02-21	Initiated	Daiwa Securities	Buy
Mar-15-21	Initiated	Needham	Buy
Mar-03-21	Reiterated	H.C. Wainwright	Buy
Feb-25-21	Initiated	Piper Sandler	Overweight
Dec-07-20	Initiated	H.C. Wainwright	Buy
Jul-27-20	Initiated	Cantor Fitzgerald	Overweight
Feb-12-20	Initiated	China Renaissance	Buy
Feb-11-20	Initiated	Jefferies	Buy

View All

I-Mab ADR Stock (IMAB) Latest News

NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday

Benzinga

I-Mab ADR Stock (IMAB) Financials Data

I-Mab ADR (IMAB) Revenue 2024

IMAB reported a revenue (TTM) of -$35.63 million for the quarter ending June 30, 2023.

I-Mab ADR (IMAB) Net Income 2024

IMAB net income (TTM) was -$315.57 million for the quarter ending June 30, 2023, a -26.83% decrease year-over-year.

I-Mab ADR (IMAB) Cash Flow 2024

IMAB recorded a free cash flow (TTM) of -$167.78 million for the quarter ending December 31, 2022.

I-Mab ADR (IMAB) Earnings per Share 2024

IMAB earnings per share (TTM) was -$3.8057 for the quarter ending June 30, 2023, a +0.41% growth year-over-year.

I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases. The company's product candidates in Phase I clinical trials include Enoblituzumab, a humanized B7-H3 antibody to treat immuno-oncology; TJ107, a long-acting recombinant human IL-7 to treat cancer treatment-related lymphopenia and cancer immunotherapy; TJC4, a CD47 monoclonal antibody with RBC-sparing differentiation; TJD5, a CD73 antibody for cancer treatment; and TJM2, a GM-CSF monoclonal antibody for rheumatoid arthritis and CAR-T-related therapies. Its product candidates in pre-clinical development comprise TJ210, an antibody targeting myeloid derived suppressor cells in cancers and autoimmune diseases; and TJX7, a novel CXCL13 antibody for autoimmune diseases. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.